Michael Pearson is to step down as  chairman of the board and chief executive officer of Valeant Pharmaceuticals International Inc.   The company has appointed activist investor William Ackman to its board. Photograph: Reuters

As recently as last summer, J Michael Pearson styled himself as a brash and bold executive with a new way of thriving in pharmaceuticals: buying othe(...)

Michael Pearson,  chief executive officer of Valeant Pharmaceuticals International. Photographer: Scott Eells/Bloomberg

Shares in embattled drugmaker Valeant Pharmaceuticals International fell up to 21 per cent as it said it was under investigation by the US Securities (...)

Michael Pearson, chairman and chief executive officer of Valeant Pharmaceuticals International, who has returned from a two-month absence due to illness. Photographer: Scott Eells/Bloomberg

Valeant Pharmaceuticals is withdrawing its financial forecast and will delay releasing fourth-quarter results, as chief executive Michael Pearsonretur(...)

Elan retains a royalty interest after selling its ownership of Tysabri to partner Biogen Idec for $3.25 billion.

Drug royalties group Elan has urged shareholders to reject the hostile takeover offer from Royalty Pharma. (...)

Elan executives at a recent egm in the Westin Hotel in Dublin [ FROM LEFT] G.Kelly Martin chief executive, Robert A Ingram, chairman and Liam Daniel, company secretary . Photograph: Cyril Byrne/Irish Times

The board of drugmaker Elan has unanimously rejected a formal bid from Royalty Pharma , saying the US investment firm's offer of $11.25 a share(...)